As scientists from around the world rush to find a cure for the coronavirus, picking up on an article by SKY News, there is news of research into antibodies which target the SARS coronavirus and scientists have identified one that blocks COVID-19.
"Scientists have discovered an antibody which prevents the coronavirus from infecting human cells in "groundbreaking research" which could lead to the development of new treatments," the article reads.
Building on research into the SARS coronavirus, scientists from Utrecht University in the Netherlands, as well as the Erasmus Medical Centre and the company Harbour BioMed (HBM), have identified a potential method of neutralising COVID-19.
They discovered that an antibody which prevents the SARS virus from infecting human cells could also block the novel coronavirus from infecting human cells too, according a peer reviewed study published on Monday in the journal Nature Communications.
Testing their collection of antibodies on cultured human cells, researchers discovered one which binds to a specific part which is present in both SARS and the virus causing COVID-19.
- The discovery could offer an initial step towards developing a fully-human antibody to treat or prevent the disease.
- The neutralising antibody "has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus," said Dr Berend-Jan Bosch, co-lead author on the study.
- The discovery provided "a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment," – said Dr Berend-Jan Bosch. "The antibody used in this work is 'fully human', allowing development to proceed more rapidly and reducing the potential for immune-related side effects," he added.
- The fully-human antibody is different from conventional therapeutic antibodies, which are often first developed in other species before being "humanised" so they can be transmitted to people.
- It was developed using Harbour BioMed's H2L2 transgenic mouse technology - effectively a mouse which has been genetically engineered to contain human genes, enabling researchers to develop "human" antibodies without testing them on living people.
- "This is groundbreaking research," said Dr Jingsong Wang, the chief executive of HBM.
This is undoubtedly good news and should help to put a foundation under markets. However, with trade wars back on the agenda, there is no escaping the prospects of a prolonged season of risk-off, volatility and uncertainty until, a) a cure is implemented, b) a vaccine is developed, c) China is proven innocent of the speculated accusations of the US following an investigation and d) global trade and the world economy can start to heal.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.